Comparative study and effects of macrophage colony-stimulating factor (M-CSF) administration on NK1.1+ cells in mouse spleen and bone marrow

Immunopharmacology and Immunotoxicology

Volumn 24, Issue 4, 2002, Pages 547-566

  Sakurai, Takuma ^a   Misawa, Eriko ^a   Yamada, Muneo ^a   Hayasawa, Hirotoshhi ^a   Motoyoshi, Kazuo ^b  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CELL SURFACE MARKER; COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL COUNT; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SORTER; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN;

ANIMALS; BONE MARROW CELLS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; KILLER CELLS, NATURAL; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SPLEEN;

ANIMALIA;

EID: 0036913476     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-120016035     Document Type: Article

References (46)

1. Robertson, M.J.; Ritz, J. Biology and clinical relevance of human natural killer cells. Blood 1990, 76, 2421-2438.
2. Moretta, L.; Ciccone, E.; Mingari, M.C.; Biassoni, R.; Moretta, A. Human natural killer cells: Origin, clonality, specificity, and receptors. Advances in Immunol. 1994, 55, 341-380.
3. Brittenden, J.; Heys, S.D.; Ross, J.; Eremin, O. Natural killer cells and cancer. Cancer 1996, 77, 1226-1243.
4. Rosenberg, E.B.; Herberman, R.B.; Levine, P.H.; Halterman, R.H.; McCoy, J.L.; Wunderlich, J.R. Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int. J. Cancer 1972, 15, 648-658.
5. Herberman, R.B.; Nunn, M.E.; Lavrin, D.H. Natulal cytotoxic reacrivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 1975, 16, 216-229.
6. Herberman, R.B.; Nunn, M.E.; Holden, H.T.; Lavrin, D.H. Natulal cytotoxic reacrivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 1975, 16, 230-239.
7. Ferrini, S.; Miescher, S.; Zocchi, M.R.; von Fliedner, V.; Moretta, A. Phenotypic and functional characterization of recombinant interleukin 2 (rIL-2)-induced activated killer cells: Analysis at the population and clonal levels. J. Immunol. 1987, 138, 1297-1302.
8. Kubota, A.; Kubota, S.; Lohwasser, S.; Mager, D.L.; Takei, F. Diversity of NK cell receptor repertoire in adult and neonatal mice. J. Immunol. 1999, 163, 212-216.
9. Giorda, R.; Trucco, M. Mouse NKR-P1 a family of genes selectively coexpressed in adherent lymphokine-activated killer cells. J. Immunol. 1991, 147, 1701-1708.
10. Ryan, J.C.; Turck, J.; Niemi, E.C.; Yokoyama, W.M.; Seaman, W.E. Molecular cloning of the NK1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules. J. Immunol. 1992, 149, 1631-1635.
11. Giorda, R.; Weisberg, E.P.; Ip, T.K.; Trucco, M. Genomic structure and strain-specific exoression of the natural killer cell receptor NKR-P1. J. Immunol. 1992, 149, 1957-1963.
12. Carlyle, J.R.; Martin, A.; Mehra, A.; Attisano, L.; Tsui, F.W.; Zuniga-Pflucker, J.C. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J. Immunol. 1999, 162, 5917-5923.
13. Pollack, S.B.; Rosse, C. The primary role of murine bone marrow in the production of natural killer cells. J. Immunol. 1987, 139, 2149-2156.
14. Moore, T.; Bennett, M.; Kumar, V. Transplantable NK cells progenitors in murine bone marrow. J. Immunol. 1995, 154, 1653-1663.
15. Ayroldi, E.; Cannarile, L.; Riccardi, C. Natural killer (NK) cell generation in bone marrow cultures: Role of IL-1a. Immunophar. Immunotox. 1991, 13, 589-606.
16. Migliorati, G.; Moraca, R.; Nicoletti, I.; Riccardi, C. IL-2-dependent generation of natural killer cells from bone marrow: Role of MAC-1-, NK1.1- precursors. Cell. Immunol. 1992, 141, 323-331.
17. Lotzova, E.; Savary, C.A.; Champlin, R.E. Genesis of human oncololytic natural killer cell from primitive CD34+CD33- bone marrow progenitors. J. Immunol. 1993, 150, 5263-5269.
18. Shibuya, A.; Kojima, H.; Shibuya, K.; Nagayoshi, K.; Nagasawa, T.; Nakauchi, H. Enrichment of interleukin-2-responsive natural killer progenitors in human bone marrow. Blood 1993, 81, 1819-1826.
19. Praloran, V. Structure, biosynthesis and biological roles of monocyte-macrophage colony stimulating factor (CSF-1 or M-CSF). Nouv. Rev. Fr. Hematol. 1991, 33, 323-333.
20. Motoyoshi, K. Biological activities and clinical application of M-CSF. Int. J. Hematol. 1998, 67, 109-122.
21. Li, H.; Schwinzer, R.; Baccarini, M.; Lohmann-Matthes, M.-L. Cooperative effects of colony-stimulating factor 1 and recombinant interleukin 2 on proliferation and induction of cytotoxicity of macrophage precursors generated from mouse bone marrow cell cultures. J. Exp. Med. 1989, 169, 973-986.
22. Li, H.; Kniep, E.; Emmendroffer, A.; Lohmann-Matthes, M.L. Differentiation of macrophage precusors to cells with LAK activity under the influence of CSF-1 and high dose IL-2. Scand. J. Immunol. 1991, 33, 511-520.
23. Lohmann-Matthes, M.L.; Emmendoerffer, A.; Hao, L. Influence of interleukin-2 on the differentiation of macrophages. Pathobiology 1991, 59, 117-121.
24. Li, H.; Pohler, U.; Strehlow, I.; Hertig, S.; Baccarini, M.; Emmendorffer, A.; Tschopp, J.; Lohmann-Matthes, M.L. Macrophage precursor cells produce perfoline and perform Yac-1 lytic activity in response to stimulation with interleukin-2, J. Leukoc. Biol. 1994, 56, 117-123.
25. + cells activity. Cancer Immunol. Immunother. 2000, 49, 94-100.
26. + Cells in Mice. Int. J. Immunophar. 2000, 22, 967-977.
27. Hatake, K.; Motoyoshi, K.; Ishizaka, Y.; Takaku, F.; Miura, Y. Purification of human urinary colony-stimulating factor by high performance liquid chromatography. J. Chromatgr. 1985, 344, 339-344.
28. McKnight, A.J.; Gordon, S. The EGF-TM7 family: Unusal structures at the leukocyte surface. J. Leukoc. Biol. 1998, 63, 271-280.
29. Yamada, H.; Kishihara, K.; Kong, Y.-Y.; Nomoto, K. Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-dificient mice. J. Immunol. 1996, 157, 1523-1528.
30. Cai, G.; Kastelein, R.A.; Hunter, C.A. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur. J. Immunol. 1999, 29, 2658-2665.
31. Sakurai, T.; Wakimoto, N.; Yamada, M.; Shimamura, S.; Motoyoshi, K. Effect of macrophage colony-stimulating factor (M-CSF) on mouse immune responses in vivo. Immunopharmacol. Immunotoxicol. 1998, 20, 79-102.
32. Xia, Y.; Vetvicka, V.; Hanikyrova, M.; Mayadas, T.; Ross, G.D. The Betaglucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 1999, 162, 2281-2290.
33. Orange, J.S.; Chehimi, J.; Ghavimi, D.; Campbell, D.; Sullivan, K.E. Decreased natural killer (NK) cell function in chronic NK cell lymphocytosis associated with decreased surface expression of CD11b. Clin. Immunol. 2001, 99, 53-64.
34. Puzanov, L.J.; Bennett, M.; Kumar, V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J. Immunol. 1996, 157, 4282-4285.
35. Salazar-Mather, T.P.; Ishikawa, R.; Biron, C.A. NK Cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J. Immunol. 1996, 157, 3054-3064.
36. Loetscher, P.; Seitz, M.; Clark-Lewis, I.; Baggiolini, M.; Moster, M. Activation of NK cells by CC chemokines. J. Immunol. 1996, 156, 322-327.
37. Maghazachi, A.A.; Al-Aoukaty, A.; Schall, T.J. CC chemokines induce the generation of killer cells from CD56+ cells. Eur. J. Immunol. 1996, 26, 315-319.
38. Shaw, S.G.; Maung, A.A.; Steptoe, R.J.; Thomson, A.W.; Vujanovic, N.L. Expansion of functional NK cells in multiple tissue compartments of mice treated with flt3-ligand: Implications for anti-cancer and anti-viral therapy. J. Immunol. 1998, 161, 2817-2824.
39. McKenna, H.J.; Stocking, K.L; Miller, R.E.; Brasel, K.; Smedt, T.D.; Maraskovsky, E.; Charles, R.M.; Lynch, D.H.; Smith, J.; Pulendran, B.; Roux, E.R.; Teepe, M.; Lyman, S.D.; Peschon, J.J. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95, 3489-3496.
40. Ross, M.; Caligiuri, M.A. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune responses. Blood 1997, 89, 910-918.
41. Mauch, P.; Lamont, C.; Neben, T.Y.; Quinto, C.; Goldman, S.J.; Witsell, A. Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: Evidence for different mechanisms of mobilization. Blood 1995, 86, 4674-4680.
42. Craddock, C.F.; Nakamoto, B.; Andrews, R.G.; Priestley, G.V.; Papayannopoulou, Thalia antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997, 90, 4779-4788.
43. Neipp, M.; Zorina, T.; Domenick, M.A.; Exner, B.G.; Ildstad, S.T. Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: Kinetics and repopulating potential. Blood 1998, 92, 3177-3188.
44. Watanabe, T.; Kawano, T.; Kanamaru, S.; Wakata, Y.; Nakagawa, R.; Makimoto, A.; Kuroda, Y.; Takaue, Y.; Talmadge, J.E. Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Blood 1999, 93, 1157-1163.
45. Arpinati, M.; Green, C.L.; Heimfeld, S.; Heuser, J.E.; Anasetti, C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95, 2484-2490.
46. Burns, L.S.; Weisdorf, D.J.; DeFor, T.E.; Repka, T.L.; Ogle, K.M.; Hummer, C.; Miller, J.S. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol. 2000, 28, 96-103.